Clinical Lymphoma, Myeloma and Leukemia

Published by: Elsevier Inc.  

People

  1. Chung
    Chung
  2. Dahi
    Dahi
  3. Giralt
    Giralt
  4. Lahoud
    Lahoud
  5. Landau
    Landau
  6. Scordo
    Scordo
  7. Shah
    Shah
  8. Devlin
    Devlin
  9. Hassoun
    Hassoun
  10. Hultcrantz
    Hultcrantz

Groups

  1. CTCR Scholars (5)
  2. Department of Medicine (5)
  3. Hematologic Malignancies, Division of (5)
  4. MSK Grad Students (5)
  5. Master of Science in Clinical and Translational Cancer Research (5)
  6. Bone Marrow Transplant (4)
  7. Center for Hematologic Malignancies (4)
  8. Survivorship Research (4)
  9. Biostatistics Service (3)
  10. Epidemiology and Biostatistics (3)
Search Within
  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (5)
Groups
  1. CTCR Scholars (5)
  2. Department of Medicine (5)
  3. Hematologic Malignancies, Division of (5)
  4. MSK Grad Students (5)
  5. Master of Science in Clinical and Translational Cancer Research (5)
  6. Bone Marrow Transplant (4)

More Groups

People
  1. David Chung (4)
  2. Gunjan Shah (4)
  3. Heather Landau (4)
  4. Michael Scordo (4)
  5. Oscar Lahoud (4)
  6. Parastoo Dahi (4)

More People

Years
  1. 2023 (1)
  2. 2021 (1)
  3. 2019 (3)
Publishers
  1. Elsevier Inc. (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL)
    Meeting Abstract

    Ansell, S.; Bröckelmann, P.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G.; Cohen, J.; De Boer, J. P.; Kuruvilla, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Interleukin-6 (IL-6) blockade with siltuximab peri-autologous hematopoietic stem cell transplantation (AHCT) may reduce symptom burden by altering the cytokine milieu in older patients with multiple myeloma (MM)
    Meeting Abstract

    Shah, G.; Holder, J.; Cho, S.; Murata, K.; Devlin, S.; Hoover, E.; Chung, D.; Dahi, P.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Successful pharmacokinetic (PK)-directed dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AHCT)
    Meeting Abstract

    Shah, G.; Lin, A.; Grumley, A.; Kamrowski, A.; Schofield, R.; Devlin, S.; Bhatt, V.; Proli, A.; Chung, D.; Dahi, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma
    Meeting Abstract

    Bal, S.; Landau, H.; Shah, G.; Scordo, M.; Dahi, P.; Lahoud, O.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save

    • Clinical Lymphoma, Myeloma and Leukemia – authorized name for:

    Name ISSN / ISBN Publisher
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cancer Media Group
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cig Media Group, Lp
    Clinical Lymphoma, Myeloma & Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 2152-2650 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 1368-8375 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 152-2650 2021
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Ltd
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2022
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2023
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Author(s)
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Authors
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2021
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.